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Increased serum concentrations of procollagen type m 
peptide in severely injured patients: An indicator of 
fibrosing activity? 
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Objectives: To determine the serum concen-
trations of procollagen type In peptide in se-
verely injured patients with different outcomes 
and to evaluate the relationship between serum 
procollagen type m peptide concentratioDS, 
sources of increased posttraumatic fibrotic ac-
tivity (wounds, lung, liver, kidney), and de-
creased elimination of procollagen type III 
peptide (liver). 
Design: Prospective study. 
Setting: Surgical ICU, university hospital. 
Patients: Fifty-seven patients (mean injury 
severity score: 38.5 points, range 13 to 75 points), 
between 16 and 70 yrs of age, treated in our 
institution within 6 hrs alter tbe accident. 
Measurements: Serial measurements were 
started on admission and continued on a 6.hr 
basis. After 48 hrs, the monitoring interval was 
e:rlended to 24 hrs until recovery (hut at least 
until day 14) or death. At each point of evalua-
tion, pulmonary and eirculatory function pa-
~eters and ehest radiographs (onee a day) 
were evaluated, the results were recorded, and 
blood sampies were drawn to determine procol-
lagen type m peptide, total bilirubin, creati-
nine, )'-glutamyl transferase, polymorphonu-
clear elastase, and other parameters. Statistic 
evaluation was done with the Wilcoxon test, 
Spearman rank correlation, and a multiple 
regression model 
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Results: Mean procollagen type m peptide 
serum concentrations (:I: so) were significantly 
different in patient. who died (8.0 " 3.8 UImL) 
eompared with thosepatients who survived with 
organ failure (2.7 :t: 1.8 U/mL) or without compli. 
cations (1.4:1: 0.5 U/mL), respectively. Significant 
eorrelations ofprocoUagen type m peptide COD· 
eentrations with the serum bilirubin concentra-
tions (r = .7), days with need of mechanical ven-
tilation (r = .64), Pao/Flo. ratio (r • -.8), 
polymorphonuclear elastase (r .... 6), serum cre-
atinine eoneentrations (r = .55), and iDjurysever-
ity score (r = .33) were observed. There W88 a 
tendency toward higher serum. procollagen type 
111 peptide concentrations in patients with 
severe skeletal injuries. 
Conclusions: Senun procollagen type m ~ 
tide concentrations in severely iDjured patienu 
may be considerably inereased in correlatiOll 
with injury severity and outcome. Procollagen 
type m peptide serum concentrations seem to 
reflect the SUID of increased collagen formatiOD 
from wound healing and fibrogenesis of Media· 
tor-related organ damage (especially lung) and 
decreased procoUagen type m peptide ezcre-
tion due to impaired liver function.. Furtherdata 
are necessary to evaluate the role of hepatie 
elimination in these patients. (Crit Care Med 
1993; 21:240-2(7) 
KEY WORDS: procollagen; multiple organ fall· 
ure; multiple trauma; adult respiratory d.istreII 
syndrome; liver fibrosis; respiratory failure; ~ 
cidents and trauma; wound healing; critical W· 
nessj hepatie failure 
Collagen synthesis is a main feature ofthe prolifer-
ative phase of wound healing. Increased quantitiea of 
collagen have been found not only in the healing 
surgical or traumatic wound (1) butalso ina varietyof 
fibrosing tissues (liver, lung, kidney, heart) that hall 
been injured from inflammatory or other destructivt 
proces ... (2). 111e direct quantification of collagen 
production depends on tissue biopsies that usually are 
not available in the clinical setting. However, in the 
course of collagen biosynthesis, collagen-derived pep-
tides are deposited in the extracel1ular matrix and 
release<! into the circuIation. Procollagen type III pep-
tide is c1eaved from the aminoterminal end of procolla-
gen type IH, one of the predominant types of collagen 
being produced during wound healing and contribut-
ingto the composition oflung connective tissue. Procol-
lagen type 111 peptide can be measured in serum 
sampies by commercially available radioimmunoas-
says and provides an estimate of collagen type [[I 
bi08ynthesis and tumover. Increased levels ofprocolla-
gen type III peptide have heen found locally in wounds 
(1) and in bronchoalveolar lavage fluid from patients 
with fibrotic pulmonary disease (3) and the adult 
respiratory distress syndrome (ARDS) (4) as weIl as in 
serum sampies of individuals after surgery (5), with 
chronie fibrotic liver disease (6-8), myocardial infare~ 
tion (9), renal insufficiency (10), severe wound infection 
(5), and ARDS (10, 11). 
Although many single measurements have been 
report.ed up to now, very few serial measurements of 
procollagen type III peptide concentrations are pub~ 
lished, and little is known about the fluctuation of 
circu1ating procollagen type III peptide eoneentrations 
in patients with severe aecidental injuries. Since 
trauma not only leads to direct damage of connective 
and skeletal tissue but also of other organs via the 
inflammatoryresponse (whoie bodyinflammation [12]), 
we hypothesized that procollagen type 111 peptide 
levels might be of value in estimating the "whoie body 
wound."To test trus hypothesis, we determined serum 
procollagen type III peptide concentrations in severely 
injured patients. 
MATERIALS AND METHODS 
We performed a prospectively designed study to 
evaluate the release of procollagen type 111 peptide into 
the circulation of patients sufl'ering from severe trau-
matic events. Patients were enroIled if the following 
criteria were met: a) clinically important injuries of at 
least two body regions (headlbrain, thorax, abdomen, 
skeletal system) or three major fraetures; b) age be~ 
tween 16 and 70 yrs; and c) treatment in our hospital 
within 6 hrs after the accident. All injuries were 
documented., and the injury severity score was calcu~ 
1ated. Severe injuries ofthe skeletal system comprised 
above-knee amputations, uni- or bilateral femur frae-
!ures, and complex fractures ofthe pelvic girdle. Serial 
Dle88urements were started on admission and contin~ 
ued on a 6-hr basis. After 48 hrs, the monitoring 
interval was extended to 24 hrs (0700 hrs) until day 14. 
Ifthe patient was still in astate of organ dysfunction at 
that time, the measurements were continued until 
clinieal recovery ordeath. Ateach evaluation point, the 
type ofventilation, FI02, Pao2, positive end-expiratory 
pressure, ehest radiograph, and a variety of other 
eirculatory and pulmonary funetion parameters as 
weIl as diagnostie and therapeutie interventions were 
recorded. Furthermore, blood sampIes were drawn for 
measurement of circulating procollagen type III pep~ 
tide, bilirubin, creatinine, polymorphonuclearelastase 
eoneentrations, and other laboratory parameters. 
After eentrifugation, serum sampies were stored at 
-sooe until assay. 
Organ failure was defined as folIows: respiratory 
failure (need for mechanical ventilatory therapy plus 
Pao/F'I02 ratio of <280 or positive end-expiratory pres~ 
sure of .<:!8 cm H20); ARDS (respiratory failure plus 
ehest radiograph with bilateral interstitial edema); 
liver failure (serum bilirubin eoncentration of >3 mgl 
dL [>51 JlmollL] of at least 48-hrs duration); and renal 
failure (serum creatinine concentration of >2 mgldL 
[> 177 JlmoVLl of at least 48 hrs duration). 
Total bilirubin, creatinine, 'Y~glutamyl transferase 
and aikaline phosphatase concentrations in serial se~ 
rum sampies were determined aecording to routine 
procedures. Polymorphonuclear elastase in complex 
witha~1~proteinase inhibitor was measured by a com~ 
mercially available ELlSA test kit (Merck, Darmstadt, 
FRG). Procollagen type III peptide in serum was deter-
mined with a new version of the radioimmunoassay 
RIAgnost" PIIIP (Behringwerke, Marburg, FRG) us-
ingthe principle of a two-stage sandwich technique as 
outhned by the manufacturer. The lower detection 
limit is about 0.1 units ofprocol1agen type III peptide! 
mL. The monoclonal antibodies used in the kit are 
highly specifie for the procollagen type III peptide, the 
com plete aminoterminal peptide eonsisting of3 oonfor-
mationally rustinct domains (col 1- 3) (MW 45,000 
daltons). The possibility of a cross-reaetion with other 
basal membrane proteins occurring in the coneentra-
tion ranges that are physiologieally relevant ean be 
virtually ruled out. The normal range of RlAgnost 
PIIIP has been determined using serum sampies from 
158 healthy men and women. By calculating the 5th 
and 95th percentile, a normal range ofO.3 to 0.8 U/mL 
has been established (information given by the manu~ 
facturer ). We considered values of > 1.0 U/mL as in~ 
creased. One unit of procollagen type III peptide!mL 
corresponds to about 15 nglmL quantified by the orig-
inal version ofthe assay (13) (personal communication 
ofthe manufacturer). To allow a comparison of results 
obtained by the tests of Behringwerke and Farmos 
Diagnostica(Finland)usedbyotherauthors(5, 7, 9,14), 
an approximate conversion rate was calculated by 
using the normal ranges of both tests, and aaauming 
that they represent the same concentrations of procol-
lagen type III peptide. Therefore, we estimated that 1 
U/mL (Behringwerke) rußOunls to 6 ngimL (Fannos). 
All factors were tested for normal distribution with 
theehi-square test for goodness offit: days ofrespirator 
therapy and injury severity score were normally dis-
tributed; serum procollagen type 111 peptide levels, 
bilirubin, creatinine, and Pa0/F'lo2 ratios followed a 
log-nonnal distribution (p > .1). Tbe log-transformed 
values were only used fOT the stepwise variable selee-
tion in a multiple regression model. All other estima-
tions were assessed with nonparametrie tests 
(Wileoxon test for two sampies, Spearman rank eoue-
lation). Tbe applieation ofthe Spearman rank eorrela-
tion analysis yields a eorrelation coefficient "rho" that 
is indieated by "r" throughout the manuseript. 
Statgraphies version 4.0 (STSC and Statistical 
Graphies) was used for a11 statistical caleulations. 
Tbe study was canied out in aecordance with the 
Ethical Committee of the Ludwig Maximilians-
University ofMunich. 
RESULTS 
Serum procoUagen type III peptide concentrations 
of 57 multiple-injured patients were detennined dur-
ing a 14-day period beginning immediately after 
trauma. The study population eonsisted of 44 male and 
13 female patients with a mean age of 38.3 yrs (range 
17 to 70). The mean injury severity score was 38.5 
poinls (range 13 to 75). In 11 patienls with a prolonged 
state of organ dysfunction, measurements were contin-
ued for a maximum of35 days until clinical recovery or 
death. 
Nine patients (mean injury severity score 43.3) died, 
all (except one) from multiple organ failure with a 
mediansurvival time ofl8 days (range 10to39). Organ 
dysfunctions were survived by 31 patients (mean 
injury severity score of 41.5), whereas 17 subjects 
(mean iJ\jury severity score of30.5) recovered without 
complications. Tbe course ofthe mean serum procolla-
gen type III peptide concentrations of these three 
patient groups is illustrated in Figure 1. At the begin-
ning, all patients (except for one patient with tourni-
quet's syndrome ofthe right lower limb after laceration 
of the femoral and popliteal artery and multiple open 
fractures ofthe femur, knee, and tibia showed aserum 
procollagen type III peptide concentration of2.8 U/mL 
alreadyin his first serum .runple) had procollagen type 
UI peptide serum concentrations within the normal 
range. After the second day, however, an increase with 
significant differences between these three groups 
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Figure 1. Mean concentration (:!: SEM) of procollagen type III peptide 
(p·Il!· P) serum concentrations of nonsurvivore (n '" 9, cloled circln), 
lIurvivors with organ failure (n '" 31, open triarIBks), and survivorI 
without organ {aHure (n = 17, closed triangte,). 'p <.05 for DDUUJ'-
vivats VII. lIurvivors with organ faiJure; (")p < .05, with one patient. 
omitted from the group of nOßsurvivors who had late adult retpin-
tory distres8 syndrome with an increase of procollagen type m 
peptide to 4.4 U/mL starting only af\.er 2 wks. 0p <.05 for noJlIIW"' 
vivars VB. survivortl withoutorgan failure;'p < .05 for Burvivorawith 
organ faHure VB. survivors without organ failure. 
could be observed for the remainderofthe studyperiod. 
Patients with lethal outcome reached a mean (± SO) 
maximum procollagen type III peptide level of8.0 ±3.8 
U/mL, which was significantly (p < .001) higher than 
the mean maximum procollagen type III peptide level 
of survivors with organ failure (2.7 ± 1.3 U/mL) or of 
patients without complications (1.4 ± 0.5 U/mL). The 
difference in the mean maximwn procollagen type m 
peptide concentration ofthe latter two groups was also 
highly significant (p < .001). 
Tbe kineties of procollagen type III peptide release 
in the individual subjects were similar to the graphs of 
the mean plots. Setting off with normal values, there 
was a more or less pronounced increase beginning 2 tc 
4 days alter trauma with a maximwn usually around 
days 10 to 17, followed by a plateau and a gradual 
decline. Patients who died showed a continuous m-
erease up to 13.7 U/mL until death. 
From the whole study population, 11 patienta pre-
sented with procollagen type III peptide concentrations 
within the normal range during the whole observation 
period. They bad injuries of mild severity (except Cor 
one with lethal brain damage), no severe injuries tothe 
skeletal system (except for one with a fracture ofthe 
acetabulwn), and rarely, respiratory failure or dys-
function ofotherorgan systems (Table 1). In thegroups 
with increasing procollagen type III peptide level., tIlo 
frequency ofthese entities increased. This concomitant 
increase ofprocollagen type III peptide peak level. with 
organ failure and injury severity could be further 
8ubstantiated by a correlation analysis, using the Spear-
manrank correlation (Table 2). Tbe highestcorrelation 
became evident for serum bilirubin values and procol-
logen type III peptide concentrations (0.70), whereas 
the correlation ofprocollagen type III peptide with the 
injury severity score was much weaker. In a multiple 
regression model with stepwise variable selection (af-
ter logarithmic transformation oflog-nonnally distrib-
uted variables), the highest bilirubin, highest creati-
nine, days of respirator therapy and lowest PO.jFI02 
ratio aft.er 7 days (in that order) contributed signifi-
cantlytothe variabilityofprocollagen type III peptide, 
explaini.ng 73% ofthe variation in procollagen type III 
peptide levels. No eorrelation was faund between 
prooollogen type III peptide levels and indicators of 
Table 1. Mean injury severity score; rate of serious injuries to the 
ake1eta1 system; rate of organ failure (total); rate of respiratAJry, 
Iiver, renal failure and adult l'espiratAJry distress syndrome (ARDS) 
118 well as the mortality rate in relation to different ooncentrations 
of prorollagen type III peptide given as pereentage of patients 
fnumber of patients in parentheses) 
Maximum Concentration of Procollagen 
Type 1Il Peptide (U/mL) 
d .O 1- 2 2-5 :>5.0 
Number of patients 11 16 21 9 
Injwy severity score 31.8 35.5 42.9 41.6 
Skeletal injuries (%) 9m 56 (9) 76 (16) 56 (5) 
Total organ failure (%t) 36 (4) 50 (8) 90 (19) 100 (9) 
Respiratory failure (%) 27 (3) 38 (6) 67 (14) 100 (9) 
ARDS(%) 0 0 10 (2) 56 (5) 
Liverfailun: (%) 18 (2) 38 (6) 76 (1B) 100 (9) 
Renal failure (%) 0 0 14 (3) 67 (6) 
Mortality (%) 9 (1) 0 5 (l) 78 (7) 
Table 2. Correlation coefficients and p values using the Spearman 
rank correlation between procollagen type III peptide (maximum) 
serum c(lDcentrations and markel1l of organ function or injury 
-ty 
Correlation 
Variable 1 Variable 2 Coefficient p Value 
Procollagen Bilirubin 0.70 <.001 
Type 1II peptide -Creatinine .... 0.55 <.001 
PO/FIO_" -0.60 <.001 
POjFI021Din b -0.56 <.001 
(after 1 wk) 
Respirator days 0.64 <.001 
Injury severity score 0.33 <.05 
y-GT 0.02 >.5 
Alkaline ph08phatase 0.03 >.5 
Mn, maximum; Min, minimum; y-GT, y-glutamyl transferase. 
"lmr. POPIO, ratio during the whole study period; ·Iowest 
Po/hJI ratio between day 8 after trauma and the end of the 
obeemItion period, thWl8xcluding patient. with respiratory failure 
oflbort durstion immediately after trauma. 
cholestasis (-y-glutamyl transferase, alkali ne 
phosphatase). 
Nine patients developed renal failure, ofwhom five 
needed continuous arteriovenous hemofiltration. In 
three eases, procollagen type III peptide increases 
preeeded the inerease in serum creatinine, three pa-
tients showed a simultaneous increase, and in three 
individuals, the increase in procollagen type III peptide 
concentrations followed the increase in creatinine with 
a lagofseveral days. In one patient, procollagen type III 
peptide values remained low despite high serum creat-
inine coneentrations. During hemofiltration, the se-
rum concentrations of procollagen type III peptide 
increased substantially, whereas creatinine concen-
trations remained stahle. 
Tbe presence of severe skeletal injuries (bilateral 
above-knee amputations, bilateral and unilateral frae-
tures of the femur, eomplex fractures of the pelvic 
girdle) led to signifieant (p < .01) increases of mean 
procollagen type III peptide levels from 2.6 ± 2.6 (sn) to 
3.5 :t: 2.9 U/mL. When the mean procollagen type III 
peptide coneentrations are eontrolled for bilirubin 
(Table 3), however, only a tendeney toward higher 
serum eoncentrations of procollagen type III peptide 
due to skeletal traumaeould be found in the low but not 
the high bilirubin group. The presenee of severe 
tharacie injury (abbreviated injury seale 3) did not 
signifieantly influence procollagen type III peptide 
levels (3.8 ± 3.2 vs. 2.7 ± 2.5,p > .05). 
In patients with overt ARDS, respiratory failure 
without ARDS, and without pulmonary impainnent, 
the mean maximum procollagen type III peptide eon-
centrations were7.6±3.5,3.3:t: 2.5,and 1.6 ±O.7U/mL, 
respectively. The mean proeollagen type III peptide 
concentrations over time of these three graups are 
depieted in Figure 2. The relationship of serum biliru-
bin eoneentrations and respiratory function is ana-
lyzed in Tahle 4. In addition to the correlatian of 
bilirubin eoneentrations with procollagen type III pep-
tide eoneentration in serum, the presenee of respira-
tory failure adds signifieantly to the procollagen type 
Table S. Dependency of procollagen type III peptide levels on serum 
concentrations of bilirubin in patients with and without severe 
injuries to the skeletal system. ProcoUagen type 111 peptide values 
(U/mL) are given as mean :t so. The Wilooxon test for two sampies 
was used for comparison of patient. with and without skeletal 
injuries within each range ofbilirubin concentrations (number of 
patient!! in parentheses) 
Skeletal injury 
No skeletal injury 
p Value 
Bilirubin.:5:3 mgldL 
{s:51pmoVL) 
1.9 :t 0.8 (9) 
1.5 :t 0.9 (16) 
<.1 
Bilirubin:>3 mgldL 
(:>51I1moVL) 
4.2 :t 3.2 (22) 
4.4 :t 3.5 (101 
>.5 
111 peptide concentrations in patients with serum bil-
irubin concentrations >3 mg/dL (51 )1Illol!L). In pa-
tients without liver failure (bilirubin .s.3 mg/dL ~51 
llmollL), there is only a tendency toward higher procol-
lagen type 111 peptideconcentrations due torespiratory 
failure. 
Polymorphonuclear elastase, which is released from 
neutrophil granulocytes, was used as an indicator of 
the inflammatory response to trauma. There was a 
significantcorrelation between the highest procollagen 
type 111 peptide values and polymorphonuclear elas-
tase levels (r = .60,p < .001). 
DISCUSSION 
This study has demonstrated that procollagen type 
111 peptide serum levels are increased in many patients 
suffering from severe trauma. 
The kinetics of procol1agen type [11 peptide increas-
ingover time are similarin almost alt patients, starting 
off with normal values, increasing to a broad maxi-
mum, followed by a gradual decline over aperiod of 2 
to 3 wks. This decrease was only observed in surviving 
patients, whereas expiring subjects showed a steady 
increase of procollagen type 111 peptide levels until 
death. The latter finding may be partly explained by 
the fact that many of the nonsurvivors died too early 
(median surviving time 18 days) to observe a decline of 
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FiflUl'e 2. Mean eoneentration (=sEM)ofprocollagen type III peptide 
(P·llI·P) serum eoneentrations of patients with adult respiratory 
distress syndrome (AROS)(n '" 7 ,dosed triangles), aeute respiratory 
failure without ARDS (n '"' 24, open triangles ), and those patients 
with normal reapiratory funetion (n "" 26. dosed eircles). 'p < .05 for 
AROS va. aeute reapiratory failure withoutARDS; I''p < .05, with one 
patient omitted from the group with ARDS who had late ARDS with 
an inerease of procollagen type III peptide to 4.4 UlmL starting only 
after 2 wks. 0p < .05 for ARDS vs. no Beute reapiratory failure;·p < 
.05 for aeute respiratory failure withoutAROS vs. no aeute respira· 
tory failure. 
procollagen type III peptide level •. Apart frorn 11 
patients with normal values throughout the observa-
tion period, the normal range was not reached agam 
within 2 wks after trauma in surviving patient8 with 
initially increasing procollagen type 111 peptide serum 
concentrations. Others (5) have observed similar pat,.. 
terns of procollagen type 111 peptide release after 
abdominal or orthopedic surgery. They (5) saw peak: 
procollagen type 111 peptide concentrations days after 
major abdominal and 60 days after orthopedic surgery 
with values retumingto nonnal not before 6 monthsin 
the latter group. These data imply that serial meaeure-
ments are necessary to interpret procollagen type 1lI 
peptide values, whereas detached determinationsmay 
be misleading. Although procollagen type III peptideiB 
supposed to be eliminated primarily via liver endothe-
lial cells with a half-life of minutes (15), changes in 
procollagen type 111 peptide serumconcentrationsseem 
to be relatively slow in our patients. Thus, detennina· 
tion of procollagen type 111 peptide every, or every 
other, day may be sufficient to record the fluctuations 
accurately enough. 
One well-known cause of procoUagen type 111 pep-
tide release is wound healing in fractures and following 
orthopedic operations (5). Therefore, we investigated 
the influence of severe trauma ofthe skeletal system in 
our patients. Although procollagen type 111 peptide 
concentrations were higher in patients with severe 
fractures, this difference was reduced after breakdown 
ofthe data, accounting for the major correlating facWr 
(bilirubin). Yet, for low concentrations of bilirubin 
there remained a tendency toward higher prooollagen 
type 111 peptide levels in patients with skeletal injuries. 
These findings are not in contrast to the data of 
Haukipuro et al. (5) who reported a correlation of 
procollagen type III peptide concentrations with tbe 
Table 4. Relation of maximum procollagen type 1II peptide levtII 
with bilirubin in patients with and without respiratory failure. 
Procollagen type III peptide values CU/mL) are given a6 mean:t: IID. 
The Wilcoxon test for two sampies was used for comparison Ii 
patient.. with and without respiratory failure within each groupl:l 
bilirubin coneentrations (number of patients in parentheseal 
Bilirubin Serum Concentrations 
.s:.3 mgfdL 3- 10 mgldL 
(.s:51Ilmol!L) (51- 170 JlIDol!L) 
No respiratory 
failul"1! 1.4 = 0.6 (16) 1.4 = 0.6 (6) 
Respiratory 
failure 2.0 :t: 1.2" (9) 3.5 = 2.4~ (12) 
P Value > .1 < .01 
>10mw'dL 
(>170 }lmolllJ 
2.5 :t 0.5 (4) 
7.3 % 3.~(lO) 
<.01 
QIncluding one patient with aeute respiratory distres8 ~ 
"ineluding five patients with aeute 1"1!8piratory distreu syndroall-
.u ...... , • " ..... 
type of surgery and tissue damage. Qnly one of our 11 
patients with consistently low concentrations G;;l.O U/ 
roL) of procollagen type 111 peptide sustained a major 
fracture, whereas the other patients with inereased 
serum procollagen type III peptide usually had major 
skeletal trauma. Furthermore, in Haukipuro's pa~ 
tients, the mean maximum value was about 1.3 U/mL 
(for conversion rate, see Results), whieh eorresponds 
with the procollagen type III peptide peak levels of our 
patients withoutcomplieations (1.4 U/mL) but is mueh 
lower than in our more severely injured subjects. 
Therefore, the effects of wound healing, whieh reaeh 
statistical significance in their study, seem, in absolute 
terms of procollagen type III peptide coneentration, 
rather low as compared with those effects of other 
major influencing faetors in our patients. We conclude 
that procollagen type 111 peptide release due to healing 
of skeletal injuries contr'ibutes to the total procollagen 
type III peptide coneentration in serum, but may be 
concealed by other dominating faetors in severely 
injured patients. 
These other detenninants may be ''wounds'' of a 
differententity, namelyoftissue damage notcaused by 
directmechanical trauma but mediated by bioehemieal 
effectors of the inflarnmatory response, hypoxia, and 
others. Such wounds and their healing have been 
described using proeollagen type In peptide as a 
marker of collagen formation in aeute viral hepatitis 
(6), in cluonic active eirrhosis (postviral, alcoholic) 
(7,16), alter myocardial infarction (9), in fibrotic lung 
disease (3) in man, and in kidney darnage in animals 
(17). 
The liver from patients with chronie fibrosing liver 
affections is thought to be a major source ofproeollagen 
type III peptide production. Procollagen type III pep~ 
tide concentrations, comparable with the concentra~ 
tions found in our patients, have been noticed fre~ 
quently, and a signifieant correlation between 
histologically confirmed hepatie fibrosis and procollagen 
type III peptideconeentrations was reported (6, 7, 16). 
However, the influence of posttraumatic or septie liver 
failureon procollagen type III peptide concentrations is 
not known. In one study, highly inereased procollagen 
type III peptide serum eoneentrations in patients with 
posttraumatic multiple organ failure Oiver failure 
always present) have heen report.ed (11). Yet, these 
authors could not differentiate, whether these high 
procollagen type III peptide concentrations were due to 
fibrotic processes or to the impairment of procollagen 
type m peptide extraction via liver endothelial cells, 
the main pathway of procollagen type III peptide 
elimination from the circulation (14, 15). 
Ourdatamightsuggest a dependenee of procollagen 
type m peptide serum concentrations on liver function 
in trauma patients, sinee we found the highesteorrela~ 
tion of all parameters for procollagen type III peptide 
concen trations with bilirubin. Similar correlations ha ve 
been observed in studies dealing with primary liver 
disease (7). Sinee intaet procollagen type III peptide is 
mainly degraded in the liver (4) and a decreased 
biliary excretion was suggested to take pIaee during 
severe liver damage (6), it may be deduced from the 
comparison ofthe procollagen type 111 peptide coneen· 
trations with those values ofbilirubin in our patients 
that at least in subjects with lethaI organ failure the 
rapid increase of procollagen type III peptide coneen~ 
trations reflects in part dysfunction of procollagen type 
III peptide elimination via the liver. It is not elear, 
however, whether a decreased rate of elimination of 
procollagen type III peptide via the liveris really amain 
eause forincreased procollagen type III peptideconcen~ 
trations in serum. Despite very high bilirubin values, 
a two~ to threefold increase in biliary exeretion of 
procol1agen type 111 peptide into bile was observed in 
humans with liver cirrhosis eompared with healthy 
controls (8), indieating that the mechanism ofproeolla~ 
gen type III peptide elimination may not be seriously 
disturbed in such patients. Recently, however, it has 
been shown that biliary excretion does not contribute 
significantly to the hepatic extraction of circulating 
procollagen type 111 peptide in the normal li ver (8). 
Therefore, the correlation of procollagen type III pep~ 
tide concentrations with serum bilirubin coneentra~ 
tions might not indicate the impainnent of a eommon 
mechanism of hepatie elimination. Furthermore, no 
correlation of procollagen type III peptide serum con~ 
centration with the hepatic extraction ratio could be 
observed in another study (4), implying that de~ 
creased extraction may be only one meehanism to 
inerease serum procollagen type III peptide. Thus, 
many authors (6, 7, 16) claimed that inereased procol~ 
lagen type 111 peptide concentrations in serum are 
caused by an increased production due to fibrogenesis 
in many forms of liver disease. Although we cannot 
direetly eonfinn fibrotic activity in the livers of our 
trauma patients with high procollagen type III peptide, 
there is evidence that in severe posttraumatic liver 
failure, necrosis and fibrosis (and thus, fibroblastic 
activity) take plaee in the liver (9). No correlation of 
procol1agen type 111 peptide with cireulating liver en-
zyme values eould be verified in our patients, excluding 
posthepatie eholestasis. 
Besides a high eorrelation of procollagen type III 
peptide with serum bilirubin eoncentrations, a good 
correlation with renal function was observed in our 
patients. A slight increase of procollagen type 111 pep~ 
tide has been deseribed in patients with renal failure 
(10). It is known that some procollagen type 111 peptide 
degradation products are excreted via the urine 
(8, 13, 14). However, the results ofmost investigations 
demonstrate that the renal pathway of excretion of 
intact procollagen type III peptide (CoI1-3 peptide) is 
much less importantthan the liver's role(8, 14). On the 
other hand, damage of the kidoey io an experimental 
modelied to an iocreased release of a collagen synthe-
sis-stimulating factor (17). Thus, fibroblast activity 
duriog repair of posttraumatic kidney damage might 
be a contributor to increased procollagen type III 
peptide formation. 
Very high levels ofprocollagen type UI peptide have 
been reported in eight patients with ARDS (10). 
Jochum et a1. (11) found similar high procollagen type 
IH peptide serum concentrations in trauma patients 
with ARDS and multiple organ failure (0 = 12) which 
were, however, only somewhat (but not significaotly) 
higher than in patients without ARDS (0 = 12) but 
sufferiog from other posttraumatic organ dysfunc-
tions. We have measured comparably high values in 
ourpatients with ARDS. Furthermore, we found a high 
correlation ofprocollagen type III peptide with respira-
tory function (PaojFlo2 ratio, total days of respirator 
therapy). ARDS is the most severe manifestation of 
respiratOlY failure, but the pathogenetic factors under-
lying ARDS and respiratoryfailure withoutARDS may 
be qualitatively the same. Therefore, we would expect 
fibroblast activity not only in (radiologically) overt 
ARDS but also in milder forms of pulmonary dysfunc-
tion. An increase of procollagen type IH peptide found 
in all patients with respiratory failure may indicate 
that such an increased collagen synthesis actually 
takes place. The increase of procollagen type IH peptide 
concentrations in patients with respiratory failure 
seems to be independent of liver function since the 
presence of pulmonary dysfunction exerts a significant 
influence on procollagen type IU peptide concentra-
tions within patient groups with similar bilirubin 
concentrations. 
Since neutrophil granulocyt.es are thought to playa 
major role in the inflammatory destruction of lung 
connective tissue (20), thus indirectly causing repara-
tive processes such as fibrosing activity, polymorpho-
nuclear elastase levels were determined to indicate 
neutrophil activity. The high correlation ofprocollagen 
type IH peptide concentrations with polymorphonu-
dear elastase concentrations suggest some relation-
ship between the posttraurnatic inflammatory response 
(and its sequelae) and the secondaryincreaseofprocol-
lagen type IU peptide concentrations. Whether there is 
a causality between mediator release (e.g., polymor-
phonuclear elastase), tissue destruction, reparative 
fibrosing activity, and procollagen type III peptide 
concentrations remains speculative. 
Although the highest procollagen type III peptide 
values of all have been observed in ARDS patientl, 
respiratory function was only the third mostimportant 
dererminant of procollagen type III peptide variability 
in a multiple regression model, indicatingthat ~ 
nary fibrosis is not the sole or main contributor to 
procollagen type III peptide formation.AlthoughARDS 
is not an isolated entity but usually part of multiple 
organ failure (21), Entzian and co-workers (10) 8UP-
plied no detailed information on liver and renal func-
tion in their ARDS patients, but at least three ofthem 
had multiple organ failure, indicatingthatothermech-
anisms for the procollagen type IH peptide increaae 
may have been present in their patients. Thus, procol-
lagen type IH peptide cannot be used as a specific 
marker for ARDSor fibroblasticlungprocesses in these 
patients. 
In summary, increased procollagen type HI peptide 
serum concentrations seem to represent increased 
collagen fonnation in severely injured patients as well 
as decreased excretion of procollagen type HI peptide 
via the liver. Moreover, they do not reflect the damage 
to a single organ but are the integral of reparative 
activities from the whole body. Healing of traumatic 
and surgical wounds as weil as the reactions in restor-
ing organ integrity after destruction by proteases, 
oxygen radicals, and other mediators in the wakeofthe 
traumatic shock seem to contribute to procollagen type 
III peptide release. Therefore, monitoring of pro-
collagen type IH peptide serum concentrations in 
severely injured patients might be of value in estimat. 
ing the "whoie body wound" that has been inflicted on 
the organism by direct tissue damage and inflam-
matory mediator-induced. trauma. However, as long 88 
the role of hepatic extraction of procollagen type m 
peptide is not completely defined, such an interpreta-
tion of increased procollagen type 111 peptide conren-
trations has to be considered with caution, not only in 
the trauma patients but also in other severely ill 
subjects. Independently from the discussion about the 
pathobiochemistry, procollagen type III peptide serum. 
concentrations may serve as an indicator of injury 
severityand prognosis. 
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